1. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Issue 10212 (23rd November 2019) Authors: Burtness, Barbara; Harrington, Kevin J; Greil, Richard; Soulières, Denis; Tahara, Makoto; de Castro, Gilberto; Psyrri, Amanda; Basté, Neus; Neupane, Prakash; Bratland, Åse; Fuereder, Thorsten; Hughes, Brett G M; Mesía, Ricard; Ngamphaiboon, Nuttapong; Rordorf, Tamara; Wan Ishak, Wan Zamaniah; Hon... Journal: Lancet Issue: Volume 394:Issue 10212(2019) Page Start: 1915 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗